Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Total Liabilities (2023 - 2025)

Historic Total Liabilities for Nuvation Bio (NUVB) over the last 3 years, with Q3 2025 value amounting to $275.7 million.

  • Nuvation Bio's Total Liabilities rose 30031.8% to $275.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $275.7 million, marking a year-over-year increase of 30031.8%. This contributed to the annual value of $76.8 million for FY2024, which is 36961.25% up from last year.
  • According to the latest figures from Q3 2025, Nuvation Bio's Total Liabilities is $275.7 million, which was up 30031.8% from $274.3 million recorded in Q2 2025.
  • In the past 5 years, Nuvation Bio's Total Liabilities ranged from a high of $275.7 million in Q3 2025 and a low of $16.0 million during Q1 2023
  • Its 3-year average for Total Liabilities is $83.5 million, with a median of $62.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in Nuvation Bio's Total Liabilities was 36961.25% (2024), while the steepest drop was 1937.32% (2024).
  • Over the past 3 years, Nuvation Bio's Total Liabilities (Quarter) stood at $16.4 million in 2023, then soared by 369.61% to $76.8 million in 2024, then surged by 258.78% to $275.7 million in 2025.
  • Its Total Liabilities was $275.7 million in Q3 2025, compared to $274.3 million in Q2 2025 and $73.0 million in Q1 2025.